Who are pethidine and haloperidol injection's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pethidine-and-haloperidol-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

pethidine and haloperidol injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pethidine and haloperidol injection (pethidine and haloperidol injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic + typical antipsychotic combination. Area: Pain management / Psychiatry.

marketed Opioid analgesic + typical antipsychotic combination Mu opioid receptor (pethidine); dopamine D2 receptor (haloperidol) Pain management / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

pethidine and haloperidol injection (pethidine and haloperidol injection) — Hospital General Universitario Gregorio Marañon. Pethidine acts as an opioid analgesic while haloperidol acts as a dopamine antagonist antipsychotic, together providing analgesia and sedation with antipsychotic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pethidine and haloperidol injection TARGET	pethidine and haloperidol injection	Hospital General Universitario Gregorio Marañon	marketed	Opioid analgesic + typical antipsychotic combination	Mu opioid receptor (pethidine); dopamine D2 receptor (haloperidol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic + typical antipsychotic combination class)

Hospital General Universitario Gregorio Marañon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pethidine and haloperidol injection — Competitive Intelligence Brief. https://druglandscape.com/ci/pethidine-and-haloperidol-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab